MedTrace Logo

Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer

NCT04360629 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2022-06-01

No results posted yet for this study

Summary

Tranexamic acid has been used in surgery for more than 30 years. It's effect on reducing bleeding and blood transfusing has been demonstrated.

In our hospital, the amount of cytorsductive surgery for ovarian cancer is big. During the perioperation , bleeding probability is high, and the supply of blood products is limited. In order to reduce bleeding, we're planning to use tranexamic acid in the operations.

In this experiment, we will observe the efficacy of tranexamic acid in cytoreductive surgery for ovarian cancer, find the best dosage which can reach the desired effect, and the possible side-effect.

Conditions

  • Advanced Ovarian Cancer

Interventions

DRUG

Tranexamic Acid

Tranexamic Acid will be given through central vein

DRUG

normal saline

normal saline will be given through central vein

Sponsors & Collaborators

  • Jun Zhang

    lead OTHER

Principal Investigators

  • Jun Zhang, PhD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-03
Primary Completion
2021-12-30
Completion
2021-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04360629 on ClinicalTrials.gov